REGN vs. BMRN: Which Stock Is the Better Value Option? May 29, 2020 Stock Market Research - Zacks Investment Research Jun 08, 2020 BMRN Stock Price | BioMarin Pharmaceutical Inc. Stock ...
BioMarin (BMRN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. The upgrade of BioMarin to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Click
BMRN Stock Summary. With a market capitalization of $19,132,539,365, Biomarin Pharmaceutical Inc has a greater market value than 90.52% of US stocks. With a price/earnings ratio of 167.82, Biomarin Pharmaceutical Inc P/E ratio is greater than that of about 96.84% of stocks in our set with positive earnings.
BioMarin Pharmaceutical Inc. (BMRN): Zacks comments Zacks comments - >>> BioMarin Downgraded to Hold Grant Zeng, CFA Friday February 20, 2009, 9:58 am EST We downgrade BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN - News) shares from Buy to Hold based on worse-than-expected 4th quarter financials and the not-rosy outlook for 2009. BioMarin Pharmaceutical (NASDAQ:BMRN) Downgraded by ... 3 hours ago · Shares of BioMarin Pharmaceutical traded up $2.57 on Thursday, reaching $107.66. 0 shares of the stock traded hands, compared to its average volume of 1656171. Shares of BMRN BioMarin Pharmaceutical closed at $107.66 on Friday.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.44 EPS for the quarter, beating the Zacks' consensus estimate of $0.12 by $0.32. BioMarin (BMRN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.